Summary : Spain’s Rovi (ROVI.MC) has agreed a 10-year extension to its deal with Moderna (MRNA.O) to manufacture future drugs developed with…
admin
-
-
IndiaMankind Pharma
Mankind Pharma to acquire Combihale and Daffy brands from Dr Reddy’s Laboratories
by adminby adminSummary : Mankind Pharma on Wednesday said it has inked a pact with Dr Reddy’s Laboratories to acquire two brands — Combihale and Daffy. While Combihale…
-
AstraZenecaIndia
Glenmark inks pact to commercialise AstraZeneca’s asthma drug in Colombian market
by adminby adminSummary : Glenmark Pharmaceuticals on Monday said its subsidiary has inked a pact to commercialise AstraZeneca’s asthma drug Pulmicort Respules in the…
-
RegulatoryU.S FDA
Zydus Pharmaceuticals (USA) Inc gets final US FDA approval to market Roflumilast tablets
by adminby adminSummary: Zydus, being one of the first applicants for Roflumilast Tablets, 500 mcg, is eligible for 180 days of shared generic drug…
-
India
Macleods Pharma files papers for IPO, likely to be one of the biggest in sector
by adminby adminSummary : The Rs 6,480-crore IPO of Gland Pharma, which was launched in November 2020, holds the record for the biggest ever…
-
Covid DrugsPharma Science & Research
Antibodies improve in quality for months after COVID-19 vaccination
by adminby adminSynopsis: For at least six months after COVID-19 vaccination, antibodies produced by immune cells become steadily more formidable and more precisely targeted…
-
Summary : Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes National Institute for Health…
-
Pharma Science & Research
Angelini Pharma’s Ontozry available for patients in Scotland with drug-resistant epilepsy
by adminby adminSummary : SMC accepts promising new therapy which offers a better quality of life to patients with epilepsy Around 55,000 people in…
-
Synopsis : Rare viral haemorrhagic disease similar to Ebola surface in the East of England. Two people in the UK have been…
-
Global MarketPharma Science & Research
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma
by adminby adminSummary- Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)…
